Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer
2015 NCCN Annual ConferenceSamuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.
Related Videos
Andrew J. Armstrong, MD, ScM, on New Treatment Options in Castration-Resistant Prostate Cancer
Andrew J. Armstrong, MD, ScM, of Duke Cancer Institute, discusses the recent practice-changing landmark studies that showed significant increases in survival for men with castratio...
John A. Thompson, MD, on Treatment Options for Advanced Melanoma
John A. Thompson, MD, of the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance, discusses the latest immunotherapeutics for advanced melanoma, including pembr...
Andrew D. Zelenetz, MD, PhD, on Emerging Treatment Options for Lymphomas
Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzum...
Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options
Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on suniti...
Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer
Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastati...
